Friday, October 29, 2021

J&J launches second PhIII COVID-19 trial




Johnson & Johnson group Janssen has initiated a second Phase III study of its experimental COVID-19 vaccine.

The two-dose regimen ENSEMBLE 2 trial will study the safety and efficacy of a two-dose regimen of the investigational vaccine for the prevention of COVID-19 in up to 30,000 participants worldwide.

Janssen will enrol participants in Belgium, Colombia, France, Germany, the Philippines, South Africa, Spain, the UK and the US, having selected clinical trial sites in countries and areas with high incidence of COVID-19 and the ability to achieve a rapid initiation.

The Phase III ENSEMBLE study of the single-dose regimen of JNJ-78436735 continues to enrol and vaccinate study participants.

The late-stage trials follow positive interim results from the ongoing Phase I/IIa clinical study, which is studying the safety profile and immunogenicity of both a single-dose and two-dose vaccination.

Interim analysis showed that a single dose of the COVID-19 vaccine candidate induced a robust immune response and was generally well-tolerated, the firm said.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...